Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy

19 May 2017

• By Sten Stovall

Shire's CEO is savoring a personal victory after Phase III data for lanadelumab in acute HAE replicated impressive Phase Ib trial results that underpinned his 2015 decision to buy Dyax.

Angioedema — Shire's lanadelumab Shines In Phase III Trial Data For Acute HAE

Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy

More from Strategy

More from Business